Search - tctmd.com

Displaying 361 - 380 of 476

Sort: Relevancy | Date

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2016

Caitlin E. Cox

October 29, 2016

News Conference News VIVA 2016

Longer Term, IN.PACT SFA Trial and Global Registry Continue to Support DCB Therapy as an Option

L.A. McKeown

October 12, 2016

News Daily News

Vascular Solutions 召回双通双通路导管

Michael O'Riordan

October 06, 2016

News Daily News

Vascular Solutions Retira los Catéteres Gemelos de Doble Vía

Michael O'Riordan

October 06, 2016

News Daily News

Vascular Solutions Recalls Twin-Pass Dual-Access Catheters

Michael O'Riordan

October 06, 2016

News Daily News

Ipsilateral Ulnar Compression Significantly Reduces Risk of Radial Artery Occlusion After Transradial PCI

Michael O'Riordan

October 03, 2016

News Conference News VIVA 2016

Bioresorbable Scaffold Shows Sustained Promise in Superficial Femoral and Iliac Artery Lesions

L.A. McKeown

September 22, 2016

News Industry News

Veryan Medical announces that the first patient has been enrolled into the Company sponsored MIMICS-3D Registry by Michael Lichtenberg MD of Arnsberg, Germany

September 15, 2016

News Conference News ESC 2016

NIPPON: With Nobori Stent, 6 Months of DAPT as Safe and Effective as 18 Months

Michael O'Riordan

August 28, 2016

News Daily News

Increased Risk of In-Hospital Complications, Including Mortality, Among A-fib Patients Undergoing PCI

Michael O'Riordan

August 24, 2016

News Features

The Bioresorbable Stent Story So Far: What Promise? What Price?

Michael O'Riordan

August 17, 2016

News Daily News

Absorb BVS 的 18 个月结果“令人安心”，但仍需要更长期的随访

Michael O'Riordan

August 01, 2016

News Daily News

“Tranquilizadores” Resultados a 18 Meses con el AVB Absorb Aunque Todavía Necesitamos Seguimientos Más Largos

Michael O'Riordan

August 01, 2016

News Daily News

‘Reassuring’ 18-Month Results Seen With Absorb BVS, but Longer-Term Follow-up Still Needed

Michael O'Riordan

August 01, 2016

News Daily News

PLATFORM: FFRCT-Guided Strategy in Suspected CAD ‘Durable’ Out to 1 Year

Michael O'Riordan

July 27, 2016

News Daily News

PLATFORM: Ante Sospecha de EAC la Estrategia de Guiado mediante FFRTC ‘Tiene una Duración’ de 1 Año

Michael O'Riordan

July 27, 2016

News Daily News

PLATFORM：FFRCT 指导的策略在疑似 CAD 患者中可“坚持”到 1 年

Michael O'Riordan

July 27, 2016

News Daily News

需要手术的支架患者的抗血小板治疗：意大利经验提供了方向

Michael O'Riordan

July 20, 2016

News Daily News

Tratamiento Antiplaquetario en Pacientes con Stents que Necesitan Cirugía: La Experiencia de Italia Marca el Camino a Seguir

Michael O'Riordan

July 20, 2016

Advertisement

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

TCTMD’s Top 10 Most Popular Stories for October 2016

Longer Term, IN.PACT SFA Trial and Global Registry Continue to Support DCB Therapy as an Option

Vascular Solutions 召回双通双通路导管

Vascular Solutions Retira los Catéteres Gemelos de Doble Vía

Vascular Solutions Recalls Twin-Pass Dual-Access Catheters

Ipsilateral Ulnar Compression Significantly Reduces Risk of Radial Artery Occlusion After Transradial PCI

Bioresorbable Scaffold Shows Sustained Promise in Superficial Femoral and Iliac Artery Lesions

Veryan Medical announces that the first patient has been enrolled into the Company sponsored MIMICS-3D Registry by Michael Lichtenberg MD of Arnsberg, Germany

NIPPON: With Nobori Stent, 6 Months of DAPT as Safe and Effective as 18 Months

Increased Risk of In-Hospital Complications, Including Mortality, Among A-fib Patients Undergoing PCI

The Bioresorbable Stent Story So Far: What Promise? What Price?

Absorb BVS 的 18 个月结果“令人安心”，但仍需要更长期的随访

“Tranquilizadores” Resultados a 18 Meses con el AVB Absorb Aunque Todavía Necesitamos Seguimientos Más Largos

‘Reassuring’ 18-Month Results Seen With Absorb BVS, but Longer-Term Follow-up Still Needed

PLATFORM: FFRCT-Guided Strategy in Suspected CAD ‘Durable’ Out to 1 Year

PLATFORM: Ante Sospecha de EAC la Estrategia de Guiado mediante FFRTC ‘Tiene una Duración’ de 1 Año

PLATFORM：FFRCT 指导的策略在疑似 CAD 患者中可“坚持”到 1 年

需要手术的支架患者的抗血小板治疗：意大利经验提供了方向

Tratamiento Antiplaquetario en Pacientes con Stents que Necesitan Cirugía: La Experiencia de Italia Marca el Camino a Seguir

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content